Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms, and Clinical Trials Outlook 2031

Strategic Insights -

Adoptive gamma delta T cell therapy has emerged as a novel and promising approach in cancer treatment, leveraging the unique ability of gamma delta T cells to recognize and destroy cancer cells without the requirement of tumor-specific antigens or genetic modifications. This immunotherapy modality possesses characteristics of both innate and adaptive immunity, enabling it to provide an immediate response and immune memory. As a result, gamma delta T cells are being investigated for their potential to combat various types of cancers, including blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies.

Key Takeaways:

  • 25 gamma delta T cell therapies are in clinical trials, with the highest phase of development being Phase II/III.
  • As of June 2025, no gamma delta T cell therapy is commercially available.
  • The US and China are dominating the gamma delta T cell therapies clinical trials landscape, with 20 therapies and 15 technology platforms, respectively.
  • Key players in the gamma delta T cell therapy market include Acepodia, Adicet, Appia Bio, Cytomed Therapeutics, Century Therapeutics, Expression Therapeutics, IN8bio, JY BioMed, Legend Biotech, Luminary Therapeutics, PhosphoGam, Takeda, TC Biopharm, and ViGenCell.
  • Ongoing clinical research and development trends in gamma delta T cell therapy are focused on leukemia, lung cancer, breast cancer, colorectal cancer, pancreatic cancer, lymphoma, brain tumors, and head & neck cancer.
  • Global gamma delta T cell therapy clinical trials are led by companies like TC Biopharm, with its most advanced product candidate, OmnImmune, in a pivotal Phase 2/3 trial for AML.
  • The development of gamma delta T cell therapies is rapidly advancing, with several recent breakthroughs, such as the achievement of complete molecular remission in a patient with relapsed AML using TC Biopharm's candidate TCB008.

Statistics:

  • 25 gamma delta T cell therapies are in clinical trials, with the highest phase of development being Phase II/III.
  • As of June 2025, no gamma delta T cell therapy is commercially available.
  • The US and China are dominating the gamma delta T cell therapies clinical trials landscape, with 20 therapies and 15 technology platforms, respectively.
  • Key players in the gamma delta T cell therapy market include Acepodia, Adicet, Appia Bio, Cytomed Therapeutics, Century Therapeutics, Expression Therapeutics, IN8bio, JY BioMed, Legend Biotech, Luminary Therapeutics, PhosphoGam, Takeda, TC Biopharm, and ViGenCell.
  • Ongoing clinical research and development trends in gamma delta T cell therapy are focused on leukemia, lung cancer, breast cancer, colorectal cancer, pancreatic cancer, lymphoma, brain tumors, and head & neck cancer.

Sources:

  • ResearchAndMarkets.com's offering, "Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031"
  • "Gamma Delta T Cells In Leukemia"
  • "Gamma Delta T Cells In Lung Cancer"
  • "Gamma Delta T Cells In Breast Cancer"
  • "Gamma Delta T Cells In Colorectal Cancer"
  • "Gamma Delta T Cells In Pancreatic Cancer"
  • "Gamma Delta T Cells In Lymphoma"
  • "Gamma Delta T Cells In Brain Tumors"
  • "Gamma Delta T Cells In Head & Neck Cancer"
  • Key players in the gamma delta T cell therapy market, including Acepodia, Adicet, Appia Bio, Cytomed Therapeutics, Century Therapeutics, Expression Therapeutics, IN8bio, JY BioMed, Legend Biotech, Luminary Therapeutics, PhosphoGam, Takeda, TC Biopharm, and ViGenCell